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Abstract: The current study evaluated the glucose-lowering effect of ganoderma lucidum 
polysaccharides (Gl-PS) in streptozotocin (STZ)-induced diabetic mice. The diabetic mice 
were  randomly  divided  into  four  groups  (8  mice  per  group):  diabetic  control  group,  
low-dose  Gl-PS  treated  group  (50  mg/kg,  Gl-PS),  high-dose  Gl-PS  treated  group  
(150 mg/kg, Gl-PS) and positive drug control treated group (glibenclamide, 4 mg/kg), with 
normal mice used as the control group. Body weights, fasting blood glucose (FBG), serum 
insulin and  blood lipid  levels of  mice were  measured. After 28 days of treatment with  
Gl-PS, body weights and serum insulin levels of the Gl-PS treated groups was significantly 
higher than that of the diabetic control group , whereas FBG levels was significantly lower. 
Moreover, total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol 
(LDL-C)  levels  of  the  Gl-PS  treated  groups  had  dropped,  whereas  the  high  density 
lipoprotein  cholesterol  (HDL-C)  levels  had  increased.  In  addition,  according  to  acute 
toxicity studies, Gl-PS did not cause behavioral changes and any death of mice. These data 
suggest that Gl-PS has an antihyperglycemic effect. Furthermore, considering the Gl-PS 
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effects on lipid proﬁle, it may be a potential hypolipidaemic agent, which will be a great 
advantage in treating diabetic conditions associated with atherosclerosis or hyperlipidemia. 
Keywords:  antihyperglycemic;  ganoderma  lucidum  polysaccharides;  streptozotocin; 
diabetic mice 
 
1. Introduction 
Diabetes  mellitus  (DM)  is  a  metabolic  disorder  characterized  by  hyperglycemia  and  alterations  
in  carbohydrate,  fat,  and  protein  metabolism,  associated  with  absolute  or  relative  deficiencies  in  
insulin secretion and/or insulin action. The condition is associated with several complications such  
as  atherosclerosis,  neuropathy,  and  cataract  formation  [1–4].  Diabetes  mellitus  is  considered  a  
“modern day epidemic” and is rightly recognized as a global public health issue. The number of adults 
with  diabetes  in  the  world  will  rise  to  300  million  by  the  year  2025  and  the  major  part  of  this  
numerical  increase will occur  in developing countries [5]. It can be classified  into type I diabetes 
(insulin-dependent diabetes mellitus) and type II diabetes (non-insulin-dependent diabetes mellitus). 
Type II diabetes accounts for about 90% of the disease, and is characterized by peripheral insulin 
resistance  and  impaired  insulin  secretion,  which  is  often  associated  with  lipid  and  lipoprotein  
disorders [6–8]. Many oral hypoglycemic agents, such as biguanides, are available for the treatment of 
diabetes [9], but these synthetic agents are associated with drawbacks such as rigid and multiple dosing 
regimen, high-cost, inaccessibility and untoward effects [10]. These factors have contributed to the 
recent increase in the use of folkloric plant products. 
Ganoderma lucidum is a favorite remedy in oriental medicine for centuries. Its fruiting body is 
called “Lingzhi” in China and “Reishi” in Japan. It has been known as a traditional remedy, used in 
Chinese  and  Japanese  traditional  medicine  for  treatment  of  several  diseases,  such  as  hepatitis, 
hypertension, chronic bronchitis, bronchial asthma, cancer and others [11,12]. Besides, in some places, 
such as Jilin province and Shangdong province of China, ganoderma lucidum water decoction has been 
used as folk medicine to treat diabetes mellitus. During the past 20 years, reports have shown that 
ganoderma lucidum extracts have beneficial therapeutic effects on diabetes. Seto et al. [13] report that 
ganoderma  lucidum  water  extracts  can  provide  beneficial  effects  in  treating  type  II  diabetes  by 
lowering the serum glucose levels through the suppression of the hepatic PEPCK gene expression. 
Mohammed et al. [14] report that the Ethylacetate and n-Butanol  fractions of ganoderma  lucidum 
aqueous  extracts  have  potent  anti-diabetic  effects.  The  Ethylacetate  fraction  has  no  significant 
erythropoetic  effect  while  the  n-Butanol  fraction  shows  a  significant  decrease  in  the  red  cell 
parameters. Jung et al. [15] report that ganoderma lucidum may stimulate glucose uptake, through both 
PI 3-kinase and AMPK in L6 skeletal muscle cells thereby contributing to glucose homeostasis. The 
major  bioactive  components  in  ganoderma  lucidum  are  polysaccharides  (Gl-PS),  ganoderic  acid 
(triterpene),  and  adenosine,  while  the  Gl-PS  are  the  major  source  of  its  biological  activity  and 
therapeutic  use  [16–20].  Several  studies  have  shown  that  Gl-PS  possess  anti-oxidant,  anti-tumor, 
immunomodulatory  and  immunotherapeutic  activities  [16,21–24].  Although  ganoderma  lucidum 
extracts  have  already  shown  anti-diabetic  effects  in  some  researches,  there  are  few  studies  on Int. J. Mol. Sci. 2011, 12                       
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therapeutic  effects  on  diabetes  of  Gl-PS.  Therefore,  the  aim  of  this  study  was  to  investigate  the 
glucose-lowering effect of Gl-PS in streptozotocin (STZ)-induced diabetic mice. 
2. Results and Discussion 
2.1. Acute Toxicology Test of Gl-PS in Mice 
Acute toxicology test of Gl-PS was evaluated in mice at doses up to 5000 mg/kg body weight p.o. 
administered for 48 h. Gl-PS did not cause behavioral changes and no death was observed. The oral 
LD50  value  of  Gl-PS  was  greater  than  5000  mg/kg  bodyweight  in  mice  and  considered  to  be  a 
practically non-toxic substance. 
2.2. Effects of Gl-PS on Body Weights in Mice  
Effects of Gl-PS on body weights in mice are shown in Figure 1. Before experiment, body weights 
were not significantly different between groups. After 7 days of treatment with Gl-PS, body weights of 
the low-dose Gl-PS treated group (LGT), high-dose Gl-PS treated group (HGT) and diabetic control 
group (DC) groups were significantly lower (P < 0.05) than that of the normal control group (NC) 
group, 13.8%, 15.9% and 27.5% lower, respectively. However, body weights of HGT group were 
significantly elevated by 32.1%, compared to that of DC group after 14 days (P < 0.05). After 28 days 
of  treatment  with  Gl-PS,  body  weights  of  the  LGT  and  HGT  groups  was  significantly  higher  
(P  <  0.05) than  that of  the  DC  group,  29.8%  and  58.1%  higher,  respectively.  And  there  was  no 
significant difference between the NC and HGT groups. 
Figure 1. Effects of Gl-PS on body weights in mice. Data were presented as means ± SD.
 
NC group: normal control group, DC group: diabetic control group, LGT group: low-dose 
Gl-PS (50 mg/kg) treated group, HGT group: high-dose Gl-PS (150 mg/kg) treated group, 
PCT group: positive drug (4 mg/kg, glibenclamide) control treated group. 
a P < 0.05 as 
compared with NC group. 
b P < 0.05 as compared with DC group. 
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STZ is a valuable agent for experimental induction of diabetes. Its diabetogenic effect is the direct 
result of irreversible damage to the pancreatic beta cells, resulting in degranulation and loss of insulin 
secretion [23]. Insulin deficiency will lead to decreased activity of lipoprotein lipase and increased 
mobilisation of free fatty acids from peripheral fat depots. The STZ-induced diabetic animal is thus 
considered  as  an  animal  model  of  type  I  diabetes  and  hyperlipidemia  [24].  STZ-induced  diabetes  
was  characterized  by  a  severe  loss  in  body  weight,  which  has  also  been  reported  by  other  
researchers [25,26], and this reduction in body weight is due to the loss or degradation of structural 
proteins, since structural proteins are known to contribute to the body weight [27]. Previous reports 
show that protein synthesis is decreased in all tissues due to decreased production of ATP and absolute 
or relative deficiency of insulin [27,28]. In the present study, when diabetic mice were treated with  
Gl-PS, the weight loss improved, which might be as a result of its ability to reduce hyperglycemia 
2.3. Effects of Gl-PS on Fasting Blood Glucose (FBG) and Serum Insulin Levels in Mice  
Effects of Gl-PS on FBG and serum insulin levels in mice are shown in Figures 2 and 3. As shown 
in Figure 2, FBG levels in NC group maintained constant during the experimental period and was 
significantly lower than diabetic groups before experiment (P < 0.05). In the LGT, HGT and PCT 
groups,  FBG  levels  showed  a  decreasing  trend.  When  compared  to  the  DC  group,  significant 
differences were seen for the LGT and HGT groups in the 14th day (P < 0.05), 43.0% and 78.1% 
lower, respectively. After 28 days of treatment with Gl-PS, there was no significant difference between 
the NC and HGT groups. As shown in Figure 3, serum insulin levels of DC groups were significantly 
lower than that of the NC group. After 28 days of treatment with Gl-PS, serum insulin levels of the 
LGT and HGT groups were significantly higher (P < 0.05) than that of the DC group，48.2% and 
27.8% higher, respectively. 
Figure 2. Effects of Gl-PS on fasting blood glucose levels in mice. Data were presented as 
means ± SD. NC group: normal control group, DC group: diabetic control group, LGT 
group: low-dose Gl-PS (50 mg/kg) treated group, HGT group: high-dose Gl-PS (150 mg/kg) 
treated group, PCT group: positive drug (4 mg/kg, glibenclamide) control treated group.  
a P < 0.05 as compared with NC group. 
b P < 0.05 as compared with DC group. 
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Figure  3.  Effects  of  Gl-PS  on  serum  insulin  levels  in  mice.  Data  were  presented  as  
means ± SD.
 NC group: normal control group, DC group: diabetic control group, LGT 
group:  low-dose  Gl-PS  (50  mg/kg)  treated  group,  HGT  group:  high-dose  Gl-PS  
(150 mg/kg) treated group, PCT group: positive drug (4 mg/kg, glibenclamide) control 
treated group. 
a P < 0.05 as compared with NC group. 
b P < 0.05 as compared with DC group. 
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Effective  control  of  the  blood  glucose  level  is  a  key  step  in  preventing  or  reversing  diabetic 
complications and improving the quality of life diabetic patients [29–31]. The present study shows that 
Gl-PS produced a significant drop in FBG levels in diabetic mice and the dosage of 150 mg/kg is more 
effective than that of 50 mg/kg. One of the possible mechanisms of this antihyperglycemic effect could 
be  due  to  an  insulin-release  stimulatory  effect.  Therefore,  Gl-PS  on  serum  insulin  levels  on  
STZ-induced diabetic mice was investigated. In the present study, the data indicated that given Gl-PS 
the treatments induced an increment in serum insulin levels, which might increase the renewal of beta 
cells in the pancreas or permit the recovery of partially destroyed beta cells and stimulates pancreatic 
insulin secretion. 
2.4. Effects of Gl-PS on Blood Lipid Levels in Mice 
Effects of Gl-PS on blood lipid levels in mice are shown in Figure 4. TC, TG and LDL-C levels of 
DC groups were significantly higher than that of the NC group, 244.6%, 289.1% and 238.5% higher, 
respectively. After 28 days of treatment with Gl-PS, TC levels of the LGT and HGT groups were 
significantly lower (P < 0.05) than that of the DC group, 150.7% and 212.7% lower, respectively. TG 
levels of the LGT and HGT groups were significantly lower (P < 0.05) than that of the DC group, 
125.4% and 234.1% lower, respectively. LDL-C levels of the LGT and HGT groups were significantly 
lower (P < 0.05) than that of the DC group, 187.3% and 204.2% lower, respectively. And the levels of 
these  parameters  were  resettled  towards  the  control  level.  HDL-C  levels  of  DC  groups  were 
significantly lower than that of the NC group, 235.7% higher. After 28 days of treatment with Gl-PS, Int. J. Mol. Sci. 2011, 12                       
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HDL-C levels of the LGT and HGT groups were significantly higher (P < 0.05) than that of the DC 
group, 92.9% and 121.4% lower, respectively. 
Figure  4.  Effects  of  Gl-PS  on  blood  lipid  levels  in  mice.  Data  were  presented  as  
means ± SD.
 NC group: normal control group, DC group: diabetic control group, LGT 
group:  low-dose  Gl-PS  (50  mg/kg)  treated  group,  HGT  group:  high-dose  Gl-PS  
(150 mg/kg) treated group, PCT group: positive drug (4 mg/kg, glibenclamide) control 
treated group. 
a P < 0.05 as compared with NC group. 
b P < 0.05 as compared with DC group. 
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It is well known that dyslipidemia  is associated with uncontrolled diabetes  mellitus. The  blood 
levels of TC, TG and LDL-C increase, while the HDL-C levels decline, contributing to secondary 
complications of diabetes [32–34]. In the present study, diabetic mice exhibited a significant elevation 
of TC, TG, and LDL-C, while HDL-C was decreased. After the Gl-PS supplementation resulted in 
lowering the TC, TG and LDL-C levels with elevation of HDL-C levels. The data indicated that Gl-PS 
may decrease the risk of cardiovascular disease and hasten removal of cholesterol from peripheral 
tissues to liver for catabolism and excretion. These effects may be due to low activity of cholesterol 
biosynthesis enzymes or low level of lipolysis which are under the control of insulin [35]. 
3. Experimental Section  
3.1. Chemicals 
A glucose analyzer (GT-1640) and glucose check strips were purchased from Arkray Inc. (Japan). 
STZ and glibenclamide were purchased from Sigma Chemical Co. (USA). Reagents for TG, HDL-C, 
LDL-C  were  purchased  from  Beijing  Chengxinde  Biochemistry  Reagent  Co.  (Beijing,  China). 
Reagents for TC were purchased from Nanjing Jiancheng Biochemistry Reagent Co. (Nanjing, China). 
Reagents for serum insulin were purchased from Beijing Beifang Pharmaceutical Co. (Beijing, China). 
All  other  chemicals  were  of the  highest  commercial  grade  available  on the  domestic  market.  The 
freshly prepared redistilled water was used in the present study. Int. J. Mol. Sci. 2011, 12                       
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3.2. Extraction of Gl-PS 
The fruiting bodies of ganoderma lucidum were purchased from a local medicine shop in Jilin city, 
China. Sporocarps were cut into small pieces, dried at 40–50 °C for 48 h and powdered. Gl-PS were 
extracted by method of Wang et al. with slight modification [36]. Briefly, Gl-PS was extracted by hot 
water  from  the  ganoderma  lucidum  fruiting  body,  followed  by  ethanol  precipitation,  dialysis,  and 
protein depletion using the Sevag method. The total yield of Gl-PS was 0.82% (w/w) in terms of the 
ganoderma lucidum fruiting body. As a hazel-colored water-soluble powder, GL-PS was dissolved in 
distilled water and stored at 4 °C before use. 
3.3. Animals 
All experiments were performed in accordance with the Guide for the Care and Use of Laboratory 
Animals of the Chinese National Institutes of Health. Male Kunming mice weighing approximately  
18 to 22 g were obtained from Jiuzhan Biochemical Factory (Jilin, China). The animals were housed in 
a room maintained at 23 ± 2 °C with relative air humidity of 45% to 55% on a 13-hour light/11-hour 
dark cycle. Mice were provided a standard laboratory chow and water ad libitum. The approval of this 
experiment was obtained from the Institutional Animal Ethics Committee of Jilin Agricultural Science 
and Technology (Jilin, China). 
3.4. Acute Toxicology Test 
Acute toxicology test in mice was performed according to the method of Chao et al. [37]. Male 
Kunming mice were divided into test and control groups (8 mice per group). The test was performed 
by using  increasing oral doses of Gl-PS (500, 2500, and 5000  mg/kg body weight), in 10  mL/kg 
volume to different test groups. Control group received saline solution (10 mL/kg). The experimental 
mice were allowed  for food ad libitum, were all kept under regular observation  for 48 h,  for any 
mortality  or  behavioral  changes  (irritation,  restlessness,  respiratory  distress,  abnormal  locomotion  
and catalepsy). 
3.5. Induction of Diabetes Mellitus 
The mice were adapted to diet and environment for 1 week before the experiment began. After a  
24-hour fasting, diabetes was subsequently induced in the mice through intraperitoneal (ip) administration 
of STZ at a dose of 100 mg/kg body weight. STZ was freshly prepared in an ice-cold citrate buffer  
(0.1 mmol/L, pH 4.5) and immediately injected into the animals (within 5 min). A week later, high and 
steady blood glucose levels were observed in STZ-induced mice. At this point, the STZ-induced mice 
with high blood glucose levels (>11.1 mmol/L) were selected as diabetic models [38]. Measurement of 
blood glucose levels was carried out by use glucose check strips. 
3.6. Experimental Design 
STZ-induced diabetic mice (mentioned above) were randomly divided into four groups (8 mice per 
group), and normal mice were used as the control group. Int. J. Mol. Sci. 2011, 12                       
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Group I (n = 8): normal control group (NC), normal mice were allowed to free access to a normal 
diet and treated with saline solution for 28 days. 
Group II (n = 8): diabetic control group (DC), the diabetic mice were allowed to free access to a 
normal diet and treated with saline solution for 28 days. 
Group III (n = 8): low-dose Gl-PS treated group (LGT), the diabetic mice were put on a normal diet 
and treated with 50 mg/kg of Gl-PS for 28 days. 
Group IV (n = 8): high-dose Gl-PS treated group (HGT), the diabetic mice were put on a normal 
diet and treated with 150 mg/kg of Gl-PS for 28 days. 
Group V (n = 8): positive drug control treated group (PCT), the diabetic mice were put on a normal 
diet and treated with 4 mg/kg of glibenclamide for 28 days.  
In a preliminary experiment, the dose of Gl-PS used in this study was tried and confirmed to be 
suitable  and  effective  in  test  mice.  FBG  levels  were  measured  for  once  every  week.  Blood  was 
collected from tip of the tail vein (starting from 9:00 a.m.) after a 12- to 14- hour overnight fast. At the 
same time, body weights of mice were measured using balance. On the last day of experiment, the 
mice were deprived of food overnight and sacrificed by cervical dislocation. Blood was collected in 
polystyrene tubes without the anticoagulant. Serum was immediately separated by centrifugation at 
3000 rpm at room temperature for 10 min. Samples were stored at −20 °C for the assay of TC, TG, 
HDL-C, LDL-C and serum insulin. TC, TG, LDL-C and HDL-C were determined by enzyme methods, 
serum insulin level was estimated by insulin-ELISA kit according to the manufacturer’s instruction. 
3.7. Statistical Analysis 
All results are expressed as mean ± SD. for eight mice in each group. To determine the effect of 
treatment, data were analyzed using one-way ANOVA repeated measures. P-values of less than 0.05 
were regarded as significant. Significant values were assessed with Duncan’s multiple range test. Data 
were analyzed using the statistical package “SPSS 12.0 for Windows”. 
4. Conclusions 
This study indicates that ganoderma lucidum polysaccharides (Gl-PS) have an antihyperglycemic 
effect.  The  possible  mechanism  of  this  antihyperglycemic  effect  is  that  Gl-PS  might  increase  the 
renewal  of  beta  cells  in  the  pancreas  or  permit the  recovery  of  partially  destroyed  beta  cells  and 
stimulates pancreatic insulin secretion. There are some studies that have shown that Gl-PS can reduce 
and delay the absorption of glucose in rats [39,40]. We need further studies to clarify the mechanisms. 
Considering the Gl-PS effect on lipid proﬁle, it may be a potential hypolipidaemic agent, which will be 
a great advantage in treating diabetic conditions associated with atherosclerosis or hyperlipidemia. 
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